Resources

Bioreactor-Generated hiPSC Cardiomyocytes for Engineered Heart Tissue Models Poster

Written by Ncardia Stem Cell Experts | May 20, 2026

This poster highlights the development of a scalable human iPSC-derived engineered heart tissue (EHT) platform, combining Ncardia’s bioreactor-generated ventricular cardiomyocytes with Propria’s MyoPod® and MyoLab® technologies to create physiologically relevant cardiac microphysiological systems. 

Download it now for a closer look at:

  • How large-scale bioreactor manufacturing enables reproducible generation of high-purity ventricular cardiomyocytes suitable for engineered tissue applications 
  • How Ncyte® ventricular cardiomyocytes form structurally organized and spontaneously beating engineered heart tissues within the MyoPod® platform
  • Functional contractility data demonstrating mature cardiac characteristics, including β-adrenergic responsiveness and physiological force-frequency relationships
  • How the MyoLab® platform enables real-time assessment of contractility, stretch response, and tissue dynamics in engineered cardiac tissues
  • Why integrating scalable cell manufacturing with microphysiological systems improves reproducibility and physiological relevance for cardiac research and therapeutic testing

Download the Poster